Tafluprost
- Generic Name
- Tafluprost
- Brand Names
- Zioptan
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34F2O5
- CAS Number
- 209860-87-7
- Unique Ingredient Identifier
- 1O6WQ6T7G3
- Background
A prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. Chemically, tafluprost is a fluorinated analog of prostaglandin F2-alpha. Tafluprost was approved for use in the U.S. on February 10, 2012.
- Indication
Tafluprost is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Ocular Hypertension
- Associated Therapies
- -
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
- Target Recruit Count
- 1
- Registration Number
- NCT04737928
- Locations
- 🇨🇳
Chi Mei Hospital Liouying Branch, Tainan, Taiwan
24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 43
- Registration Number
- NCT02802137
Switching From Preserved to Preserved-free Treatments for Glaucoma.
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Paolo Fogagnolo
- Target Recruit Count
- 40
- Registration Number
- NCT01433900
- Locations
- 🇮🇹
San Paolo Hospital, Milano, Italy
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 185
- Registration Number
- NCT01087671
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2009-01-12
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 150
- Registration Number
- NCT00596791
- Locations
- 🇫🇮
Finn-Medi Research Oy, Tampere, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath